Vor Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Vor Biopharma şirketinin toplam hissedar öz sermayesi $73.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $116.0M ve $43.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$62.81m
Eşitlik	US$72.96m
Toplam yükümlülükler	US$43.04m
Toplam varlıklar	US$115.99m

Son finansal sağlık güncellemeleri

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10

Vor Biopharma EPS misses by $0.03

May 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VOR 'nin kısa vadeli varlıkları ( $67.3M ) kısa vadeli yükümlülüklerini ( $14.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: VOR şirketinin kısa vadeli varlıkları ( $67.3M ) uzun vadeli yükümlülüklerini ( $28.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VOR borçsuzdur.

Borcun Azaltılması: VOR şirketinin 5 yıl önce borç/öz sermaye oranı 28% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VOR şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: VOR un, serbest nakit akışı her yıl % 29.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Vor Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Recent updates

Price target decreased by 9.5% to US$11.94

Vor Biopharma Inc. Appoints Han Choi as Chief Financial Officer

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

New minor risk - Share price stability

Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg™

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Comp Value Index

Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024

New minor risk - Market cap size

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

New minor risk - Financial position

Vor Bio Appoints Fouad Namouni to its Board of Directors

Vor Biopharma Inc., Annual General Meeting, May 23, 2024

New major risk - Financial position

Insufficient new directors

Vor Bio Doses First AML Patient with VCAR33 (ALLO)

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Price target decreased by 7.2% to US$13.75

New minor risk - Share price stability

Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 19% to US$14.82

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Vor Biopharma Inc. Presents Clinical Data from VBP101

Vor Biopharma Inc. announced that it expects to receive $50 million in funding from RA Capital Management, L.P.

Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel (Vor33) and Tolerated Mylotarg(Tm)

Price target decreased to US$18.13

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Vor Bio appoints Eyal C. Attar as chief medical officer

Price target decreased to US$21.88

Price target decreased to US$22.25

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2500 Value Index

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Price target decreased to US$24.25

Price target decreased to US$31.71

Vor Biopharma Inc. Announces Retirement of Christopher Slapak as Chief Medical Officer

High number of new directors

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Expects to Enroll First Patient in VOR33 Acute Myeloid Leukemia Phase 1/2A Clinical Trial in the Next Few Months

Vor Biopharma: Targeted Therapies For Transplants

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

Vor Biopharma Inc. has completed an IPO in the amount of $176.904306 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin